Atrioventricular Junction Ablation and Biventricular Pacing for Atrial Fibrillation and Heart Failure
Status:
Recruiting
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
There is evidence of superiority of AV junction ablation strategy over pharmacological
therapy only for symptoms of atrial fibrillation, but not for heart failure, hospitalization,
morbidity and mortality. Hypothesis of trial is that AV junction ablation is superior to
pharmacological therapy as regard hospitalization and mortality
Phase:
Phase 3
Details
Lead Sponsor:
Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella